H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
TheFly reported on January 23 that H.C. Wainwright lowered the price target on CRMD to $13 from $18 while keeping a Buy rating. The adjustment reflects updated guidance for 2026–2027 related to DefenCath. The firm noted that CRMD has now entered a phase where clinical results will play a larger role than commercial performance in shaping the company's future. Similarly, on January 21, RBC Capital lowered the price target on CorMedix Inc. (NASDAQ:CRMD) to $13 from $22 while maintaining an Outperform rating. The firm updated its models for several biotech companies following discussions with management. CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company developing and commercializing therapeutic products to prevent and treat serious diseases. Its lead product, DefenCath, is an FDA-approved catheter lock solution that reduces bloodstream infections in hemodialysis patients. While we acknowledge the potential of CRMD as an investment, we believe certain AI stocks offer grea
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Therapeutics Announces Share Repurchase Program [Yahoo! Finance]Yahoo! Finance
- CorMedix Therapeutics Announces Share Repurchase ProgramGlobeNewswire
- Assessing CorMedix (CRMD) Valuation After Recent Share Price Pressure And Long Term Gains [Yahoo! Finance]Yahoo! Finance
- CorMedix Analyst Day To Clarify REZZAYO And DefenCath Phase III Path [Yahoo! Finance]Yahoo! Finance
- CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 1/27/26 - Form 4
- 1/27/26 - Form 4
- 1/27/26 - Form 4
- CRMD's page on the SEC website